Potentially Pathogenic SORL1 Mutations Observed in Autosomal-Dominant Cases of Alzheimer’s Disease Do Not Modulate APP Physiopathological Processing
Cells · 2023
DOI: 10.3390/cells12242802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Charlotte Bauer und 3 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, CNRS, IPMC, Team Labeled "Laboratory of Excellence (LABEX) Distalz", Université Côte d'Azur, 660 Route des Lucioles, Sophia-Antipolis, 06560 …. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Protein Precursor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DisTALZ.
Themen: Demenz
Abstract (Originalsprache)
The SORL1 gene encodes LR11/SorLA, a protein that binds β-amyloid precursor protein (APP) and drives its intracellular trafficking. SORL1 mutations, occurring frequently in a subset of familial cases of Alzheimer’s disease (AD), have been documented, but their pathogenic potential is not yet clear and questions remain concerning their putative influence on the physiopathological processing of APP. We have assessed the influence of two SORL1 mutations that were described as likely disease-causing and that were associated with either benign (SorLA924) or severe (SorLA511) AD phenotypes. We examined the influence of wild-type and mutants SorLA in transiently transfected HEK293 cells expressing either wild-type or Swedish mutated APP on APP expression, secreted Aβ and sAPPα levels, intracellular Aβ 40 and Aβ42 peptides, APP-CTFs (C99 and C83) expressions, α-, β- and γ-secretases expressions and activities as well as Aβ and CTFs-degrading enzymes. These paradigms were studied in control conditions or after pharmacological proteasomal modulation. We also established stably transfected CHO cells expressing wild-type SorLA and established the colocalization of APP and either wild-type or mutant SorLA. SorLA mutations partially disrupt co-localization of wild-type sorLA with APP. Overall, although we mostly confirmed previous data concerning the influence of wild-type SorLA on APP processing, we were unable to evidence significant alterations triggered by our set of SorLA mutants, whatever the cells or pharmacological conditions examined. Our study , however, does not rule out the possibility that other AD-linked SORL1 mutations could indeed affect APP processing, and that pathogenic mutations examined in the present study could interfere with other cellular pathways/triggers in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, CNRS, IPMC, Team Labeled "Laboratory of Excellence (LABEX) Distalz", Université Côte d'Azur, 660 Route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France.
- Center for Research in Neurodegenerative Diseases, Department of Medicine, Toronto Western Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON M5G 1L7, Canada.
ORCID-Profile: Eric Duplan, Frédéric Checler
Förderung
- DisTALZ
Zitieren
APA
Bauer, C., Duplan, E., Saint-George-Hyslop, P., & Checler, F. (2023). Potentially Pathogenic SORL1 Mutations Observed in Autosomal-Dominant Cases of Alzheimer’s Disease Do Not Modulate APP Physiopathological Processing. Cells. https://doi.org/10.3390/cells12242802
Vancouver
Bauer C, Duplan E, Saint-George-Hyslop P, Checler F. Potentially Pathogenic SORL1 Mutations Observed in Autosomal-Dominant Cases of Alzheimer’s Disease Do Not Modulate APP Physiopathological Processing. Cells. 2023. doi:10.3390/cells12242802
BibTeX
@article{Bauer2023,
author = {Bauer, Charlotte and Duplan, Eric and Saint-George-Hyslop, Peter and Checler, Frédéric},
title = {Potentially Pathogenic SORL1 Mutations Observed in Autosomal-Dominant Cases of Alzheimer’s Disease Do Not Modulate APP Physiopathological Processing},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12242802}
}
EUVIMED